Mostly Markets
Subscribe
Stocks/Health Care/Health Care Equipment

DexcomDXCM

Health Care Equipment · San Diego, California · In the S&P 500
High qualityPricier than peers
$82.29+2.95%After hours: $83.50 (+1.47%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 20.7% over 1 year
Dexcom over 1 yearDaily close, $, to 30 Oct 2026
$60Nov2026MarMayJulSep$82.29$60NovMarJul$82.29
Source: Nasdaq daily closes
Market value$31.05B
Price to earnings32.3x
Forward P/E29.2x
Dividend yield–
Year to date+24.0%
One year+20.7%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$54.84$92.34

Quality and valuation

How Dexcom compares with other health care stocks. A description, not a recommendation.

Dexcom and 7 health care equipment peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: pricier than most

A stronger business than most health care companies, priced above most of them.

Dexcom trades at 29.2 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +13.0% vs +7.8%
  • Keeps less of each sale (gross margin): 63.4% vs 65.3%
  • More profitable (operating margin): 24.0% vs 13.3%
  • Turns more of its sales into cash: 21.5% vs 15.9%
DXCM trades at 29.2x forward earnings, above the sector medianForward p/e, Health Care Equipment peers
BSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xDXCM29.2xEW29.3xISRG37.5xSector median 19.1xBSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xDXCM29.2xEW29.3xISRG37.5xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 32.4x earnings, DXCM is cheaper than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
40x60xAverage 43.4x2025202632.4x40x60xAverage 43.4x2025202632.4x
Source: Nasdaq prices; SEC filings

Financials

From Dexcom's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 11.2% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0.0bn$0.5bn$1.0bnQ4 ’24Q2 ’25Q4 ’25$1.3bnQ3 ’26$0.0bn$0.5bn$1.0bnQ4 ’24Q2 ’25Q4 ’25$1.3bnQ3 ’26
Source: SEC filings
Growth slowed to +11.2% last quarterRevenue growth, year on year, %
0%10%20%Q4 ’24Q2 ’25Q4 ’2511.2%Q3 ’260%10%20%Q4 ’24Q2 ’25Q4 ’2511.2%Q3 ’26
Source: SEC filings
Operating margin was 24.3% last quarterOperating income as a share of revenue, %
0%10%20%Q4 ’24Q2 ’25Q4 ’2524.3%Q3 ’260%10%20%Q4 ’24Q2 ’25Q4 ’2524.3%Q3 ’26
Source: SEC filings
Free cash flow was $1.1 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$200m$400mQ4 ’24Q2 ’25Q4 ’25$273mQ3 ’26$0m$200m$400mQ4 ’24Q2 ’25Q4 ’25$273mQ3 ’26
Source: SEC filings
Last 12 monthsDXCMSector median
Revenue growth+13.0%+7.8%
Gross margin63.4%65.3%
Operating margin24.0%13.3%
Free cash flow margin21.5%15.9%
Price to earnings32.3x30.2x

Stories on Dexcom

We haven't written about Dexcom yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Equipment, by market value.

CompanyPriceTodayYTDValue
ABTAbbott Laboratories$106.20+1.56%−15.2%$184B
ISRGIntuitive Surgical$432.01−3.73%−23.7%$150B
MDTMedtronic$96.54−0.59%+0.5%$123B
SYKStryker$291.86−6.38%−17.0%$112B
BSXBoston Scientific$41.98−1.66%−56.0%$60.84B
BDXBecton Dickinson$197.88−0.23%+27.4%$53.90B
EWEdwards Lifesciences$92.01−2.57%+7.9%$53.03B
IDXXIdexx Laboratories$551.21−4.30%−18.5%$43.42B